Paul Denver1, Victor A Gault2, Paula L McClean3. 1. Centre for Molecular Biosciences, University of Ulster, Coleraine, UK. 2. SAAD Centre for Pharmacy and Diabetes, School of Biomedical Sciences, University of Ulster, Coleraine, UK. 3. Clinical, Translational and Research Innovation Centre (C-TRIC), University of Ulster, Derry/Londonderry, UK.
Abstract
AIMS: To demarcate pathological events in the brain as a result of short-term to chronic high-fat-diet (HFD) feeding, which leads to cognitive impairment and neuroinflammation, and to assess the efficacy of Xenin-25[Lys(13)PAL] in chronic HFD-fed mice. METHODS: C57BL/6 mice were fed an HFD or a normal diet for 18 days, 34 days, 10 and 21 weeks. Cognition was assessed using novel object recognition and the Morris water maze. Markers of insulin signalling and inflammation were measured in brain and plasma using immunohistochemistry, quantitative PCR and multi-array technology. Xenin-25[Lys(13)PAL] was also administered for 5 weeks in chronic HFD-fed mice to assess therapeutic potential at a pathological stage. RESULTS: Recognition memory was consistently impaired in HFD-fed mice and spatial learning was impaired in 18-day and 21-week HFD-fed mice. Gliosis, oxidative stress and IRS-1 pSer616 were increased in the brain on day 18 in HFD-fed mice and were reduced by Xenin-25[Lys(13)PAL] in 21-week HFD-fed mice. In plasma, HFD feeding elevated interleukin (IL)-6 and chemokine (C-X-C motif) ligand 1 at day 34 and IL-5 at week 10. In the brain, HFD feeding reduced extracellular signal-regulated kinase 2 (ERK2), mechanistic target of rapamycin (mTOR), NF-κB1, protein kinase C (PKC)θ and Toll-like receptor 4 (TLR4) mRNA at week 10 and increased expression of glucacon-like peptide-1 receptor, inhibitor of NF-κB kinase β, ERK2, mTOR, NF-κB1, PKCθ and TLR4 at week 21, elevations that were abrogated by Xenin-25[Lys(13)PAL]. CONCLUSIONS: HFD feeding modulates cognitive function, synapse density, inflammation and insulin resistance in the brain. Xenin-25[Lys(13)PAL] ameliorated markers of inflammation and insulin signalling dysregulation and may have therapeutic potential in the treatment of diseases associated with neuroinflammation or perturbed insulin signalling in the brain.
AIMS: To demarcate pathological events in the brain as a result of short-term to chronic high-fat-diet (HFD) feeding, which leads to cognitive impairment and neuroinflammation, and to assess the efficacy of Xenin-25[Lys(13)PAL] in chronic HFD-fed mice. METHODS: C57BL/6 mice were fed an HFD or a normal diet for 18 days, 34 days, 10 and 21 weeks. Cognition was assessed using novel object recognition and the Morris water maze. Markers of insulin signalling and inflammation were measured in brain and plasma using immunohistochemistry, quantitative PCR and multi-array technology. Xenin-25[Lys(13)PAL] was also administered for 5 weeks in chronic HFD-fed mice to assess therapeutic potential at a pathological stage. RESULTS: Recognition memory was consistently impaired in HFD-fed mice and spatial learning was impaired in 18-day and 21-week HFD-fed mice. Gliosis, oxidative stress and IRS-1 pSer616 were increased in the brain on day 18 in HFD-fed mice and were reduced by Xenin-25[Lys(13)PAL] in 21-week HFD-fed mice. In plasma, HFD feeding elevated interleukin (IL)-6 and chemokine (C-X-C motif) ligand 1 at day 34 and IL-5 at week 10. In the brain, HFD feeding reduced extracellular signal-regulated kinase 2 (ERK2), mechanistic target of rapamycin (mTOR), NF-κB1, protein kinase C (PKC)θ and Toll-like receptor 4 (TLR4) mRNA at week 10 and increased expression of glucacon-like peptide-1 receptor, inhibitor of NF-κB kinase β, ERK2, mTOR, NF-κB1, PKCθ and TLR4 at week 21, elevations that were abrogated by Xenin-25[Lys(13)PAL]. CONCLUSIONS: HFD feeding modulates cognitive function, synapse density, inflammation and insulin resistance in the brain. Xenin-25[Lys(13)PAL] ameliorated markers of inflammation and insulin signalling dysregulation and may have therapeutic potential in the treatment of diseases associated with neuroinflammation or perturbed insulin signalling in the brain.
Authors: Xiaoran Liu; Klodian Dhana; Lisa L Barnes; Christy C Tangney; Puja Agarwal; Neelum Aggarwal; Thomas M Holland; Todd Beck; Denis A Evans; Kumar B Rajan Journal: Am J Clin Nutr Date: 2022-10-06 Impact factor: 8.472
Authors: Zhen-Hua Wu; Jing Yang; Lei Chen; Chuang Du; Qi Zhang; Shan-Shan Zhao; Xiao-Yu Wang; Jing Yang; Yang Liu; Demin Cai; Jian Du; Hui-Xin Liu Journal: Front Nutr Date: 2022-06-07
Authors: Stephanie M Muscat; Nicholas P Deems; Heather D'Angelo; Meagan M Kitt; Peter M Grace; Nathan D Andersen; Shaelyn N Silverman; Kenner C Rice; Linda R Watkins; Steven F Maier; Ruth M Barrientos Journal: Neurobiol Aging Date: 2020-11-24 Impact factor: 4.673
Authors: Edit Somogyi; David Sigalet; Thomas E Adrian; Csaba Nyakas; Christiaan W Hoornenborg; André P van Beek; Henry S Koopmans; Gertjan van Dijk Journal: Obes Surg Date: 2020-07 Impact factor: 4.129
Authors: Bilal N Sheikh; Sukanya Guhathakurta; Tsz Hong Tsang; Marius Schwabenland; Gina Renschler; Benjamin Herquel; Vivek Bhardwaj; Herbert Holz; Thomas Stehle; Olga Bondareva; Nadim Aizarani; Omar Mossad; Oliver Kretz; Wilfried Reichardt; Aindrila Chatterjee; Laura J Braun; Julien Thevenon; Herve Sartelet; Thomas Blank; Dominic Grün; Dominik von Elverfeldt; Tobias B Huber; Dietmar Vestweber; Sergiy Avilov; Marco Prinz; Joerg M Buescher; Asifa Akhtar Journal: Nat Cell Biol Date: 2020-06-15 Impact factor: 28.213
Authors: Cristhyane Costa de Aquino; Ricardo A Leitão; Luís A Oliveira Alves; Vanessa Coelho-Santos; Richard L Guerrant; Carlos F Ribeiro; João O Malva; Ana P Silva; Reinaldo B Oriá Journal: Front Nutr Date: 2019-01-09